RecruitingPhase 1NCT05156203

Safety and Tolerability Study for T-1301 Capsules to Treat Advanced Solid Tumors

Studying NLRP3-associated autoinflammatory disease

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Taivex Therapeutics Corporation
Intervention
T-1301 Capsules(drug)
Enrollment
30 target
Eligibility
20 years · All sexes
Timeline
20212027

Study locations (3)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05156203 on ClinicalTrials.gov

Other trials for NLRP3-associated autoinflammatory disease

Additional recruiting or active studies for the same condition.

See all trials for NLRP3-associated autoinflammatory disease

← Back to all trials